{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T20:05:44Z","timestamp":1747166744757,"version":"3.40.5"},"reference-count":87,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.lpm.2016.09.012","type":"journal-article","created":{"date-parts":[[2016,11,9]],"date-time":"2016-11-09T14:00:45Z","timestamp":1478700045000},"page":"1043-1055","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Les traitements du futur de l\u2019asthme s\u00e9v\u00e8re"],"prefix":"10.1016","volume":"45","author":[{"given":"Caroline","family":"Sattler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxane","family":"Malrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5383-4189","authenticated-orcid":false,"given":"Gilles","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lpm.2016.09.012_bib0440","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1183\/13993003.00853-2015","article-title":"A summary of the new GINA strategy: a roadmap to asthma control","volume":"46","author":"Reddel","year":"2015","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.lpm.2016.09.012_bib0445","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1056\/NEJM200008033430504","article-title":"Low-dose inhaled corticosteroids and the prevention of death from asthma","volume":"343","author":"Suissa","year":"2000","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.lpm.2016.09.012_bib0450","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ccm.2012.06.002","article-title":"Adherence: the goal to control asthma","volume":"33","author":"Boulet","year":"2012","journal-title":"Clin Chest Med"},{"issue":"6","key":"10.1016\/j.lpm.2016.09.012_bib0455","doi-asserted-by":"crossref","first-page":"1260e3","DOI":"10.1016\/j.jaci.2014.05.041","article-title":"Inhaler reminders improve adherence with controller treatment in primary care patients with asthma","volume":"134","author":"Foster","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.lpm.2016.09.012_bib0460","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1542\/peds.2008-2961","article-title":"Adherence feedback to improve asthma outcomes among inner-city children: a randomized trial","volume":"124","author":"Otsuki","year":"2009","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.lpm.2016.09.012_bib0465","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jaci.2010.03.034","article-title":"A cluster-randomized trial to provide clinicians inhaled corticosteroid adherence information for their patients with asthma","volume":"126","author":"Williams","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.lpm.2016.09.012_bib0470","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1164\/rccm.200906-0907OC","article-title":"Shared treatment decision making improves adherence and outcomes in poorly controlled asthma","volume":"181","author":"Wilson","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2016.09.012_bib0475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2466-10-1","article-title":"Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study","volume":"10","author":"Price","year":"2010","journal-title":"BMC Pulm Med"},{"issue":"4","key":"10.1016\/j.lpm.2016.09.012_bib0480","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","article-title":"The prevalence of severe refractory asthma","volume":"135","author":"Hekking","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.lpm.2016.09.012_bib0485","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.lpm.2016.09.012_bib0490","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.jaci.2006.11.702","article-title":"Severe asthma in adults: what are the important questions?","volume":"119","author":"Chanez","year":"2007","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.lpm.2016.09.012_bib0495","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/thoraxjnl-2015-206800","article-title":"Asthma deaths: what now?","volume":"70","author":"Levy","year":"2015","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.lpm.2016.09.012_bib0500","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1183\/13993003.00220-2016","article-title":"A 1-day visit in a severe asthma centre: effect on asthma control, quality of life and healthcare use","volume":"48","author":"van der Meer","year":"2016","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.lpm.2016.09.012_bib0505","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1378\/chest.12-3073","article-title":"Mechanisms of airway remodeling","volume":"144","author":"Hirota","year":"2013","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.lpm.2016.09.012_bib0510","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1164\/rccm.201505-0963WS","article-title":"Future research directions in asthma. An NHLBI Working Group Report","volume":"192","author":"Levy","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"6093","key":"10.1016\/j.lpm.2016.09.012_bib0515","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1126\/science.1221064","article-title":"New paradigms in type 2\u00a0immunity","volume":"337","author":"Pulendran","year":"2012","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.lpm.2016.09.012_bib0520","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nri3427","article-title":"Protective and pathological roles of mast cells and basophils","volume":"13","author":"Voehringer","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.lpm.2016.09.012_bib0525","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.coi.2012.06.003","article-title":"Susceptibility and immunity to helminth parasites","volume":"24","author":"Maizels","year":"2012","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"10.1016\/j.lpm.2016.09.012_bib0530","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/ni.3049","article-title":"The immunology of asthma","volume":"16","author":"Lambrecht","year":"2015","journal-title":"Nat Immunol"},{"issue":"2","key":"10.1016\/j.lpm.2016.09.012_bib0535","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.immuni.2015.01.020","article-title":"Emerging functions of amphiregulin in orchestrating immunity, inflammation, and tissue repair","volume":"42","author":"Zaiss","year":"2015","journal-title":"Immunity"},{"issue":"7534","key":"10.1016\/j.lpm.2016.09.012_bib0540","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nature14189","article-title":"The biology of innate lymphoid cells","volume":"517","author":"Artis","year":"2015","journal-title":"Nature"},{"issue":"7470","key":"10.1016\/j.lpm.2016.09.012_bib0545","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nature12526","article-title":"Type 2\u00a0innate lymphoid cells control eosinophil homeostasis","volume":"502","author":"Nussbaum","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.lpm.2016.09.012_bib0550","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3389\/fphys.2016.00214","article-title":"The therapeutic potential of targeting cytokine alarmins to treat allergic airway inflammation","volume":"7","author":"Sy","year":"2016","journal-title":"Front Physiol"},{"issue":"4","key":"10.1016\/j.lpm.2016.09.012_bib0555","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nri2735","article-title":"How are T(H)2-type immune responses initiated and amplified?","volume":"10","author":"Paul","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"10.1016\/j.lpm.2016.09.012_bib0560","doi-asserted-by":"crossref","first-page":"8183","DOI":"10.4049\/jimmunol.174.12.8183","article-title":"Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity","volume":"174","author":"Ying","year":"2005","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.lpm.2016.09.012_bib0565","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jaci.2009.04.018","article-title":"A thymic stromal lymphopoietin gene variant is associated with asthma and airway hyper-responsiveness","volume":"124","author":"He","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"7363","key":"10.1016\/j.lpm.2016.09.012_bib0570","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nature10329","article-title":"TSLP promotes interleukin-3-independent basophil haematopoiesis and type 2\u00a0inflammation","volume":"477","author":"Siracusa","year":"2011","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.lpm.2016.09.012_bib0575","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.immuni.2012.08.015","article-title":"The transcription factor GATA3\u00a0is essential for the function of human type 2\u00a0innate lymphoid cells","volume":"37","author":"Mj\u00f6sberg","year":"2012","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.lpm.2016.09.012_bib0580","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/cpt.11","article-title":"Anti-interleukin therapy in asthma","volume":"97","author":"Dunn","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.lpm.2016.09.012_bib0585","doi-asserted-by":"crossref","first-page":"525e1","DOI":"10.1016\/j.jaip.2014.03.010","article-title":"Omalizumab in asthma: an update on recent developments","volume":"2","author":"Humbert","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.lpm.2016.09.012_bib0590","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1378\/chest.12-1372","article-title":"Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: results from a large cohort of patients with severe uncontrolled asthma","volume":"143","author":"Grimaldi-Bensouda","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.lpm.2016.09.012_bib0595","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002\u00a0step 4\u00a0treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.lpm.2016.09.012_bib0600","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2016.09.012_bib0605","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.rmed.2010.06.001","article-title":"Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data","volume":"104","author":"Molimard","year":"2010","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.lpm.2016.09.012_bib0610","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1378\/chest.12-1961","article-title":"A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, non-atopic asthma","volume":"144","author":"Garcia","year":"2013","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.lpm.2016.09.012_bib0615","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3109\/02770903.2012.757780","article-title":"Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry","volume":"50","author":"de Llano","year":"2013","journal-title":"J Asthma"},{"key":"10.1016\/j.lpm.2016.09.012_bib0620","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.rmed.2010.07.011","article-title":"Omalizumab-induced decrease of FcxiRI expression in patients with severe allergic asthma","volume":"104","author":"Chanez","year":"2010","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.lpm.2016.09.012_bib0625","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12890-016-0290-5","article-title":"Drop-out rate among patients treated with omalizumab for severe asthma: literature review and real-life experience","volume":"16","author":"Caminati","year":"2016","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.lpm.2016.09.012_bib0630","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1398-9995.2009.02144.x","article-title":"After 6\u00a0years with Xolair; a 3-year withdrawal follow-up","volume":"65","author":"Nopp","year":"2015","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.lpm.2016.09.012_bib0635","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jaci.2016.02.027","article-title":"Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses","volume":"138","author":"Gauvreau","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"9998","key":"10.1016\/j.lpm.2016.09.012_bib0640","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S0140-6736(15)00157-9","article-title":"Targeting the interleukin pathway in the treatment of asthma","volume":"386","author":"Chung","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2016.09.012_bib0645","first-page":"125","article-title":"The past, present, and future of monoclonal antibodies to IL-5\u00a0and eosinophilic asthma: a review","volume":"8","author":"Patterson","year":"2015","journal-title":"J Asthma Allergy"},{"issue":"9248","key":"10.1016\/j.lpm.2016.09.012_bib0650","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0140-6736(00)03496-6","article-title":"Effects of an interleukin-5\u00a0blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response","volume":"356","author":"Leckie","year":"2000","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.lpm.2016.09.012_bib0655","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.lpm.2016.09.012_bib0660","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.lpm.2016.09.012_bib0665","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/thx.2009.122697","article-title":"Mepolizumab in refractory eosinophilic asthma","volume":"65","author":"Pavord","year":"2010","journal-title":"Thorax"},{"issue":"13","key":"10.1016\/j.lpm.2016.09.012_bib0670","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.lpm.2016.09.012_bib0675","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.lpm.2016.09.012_bib0680","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multicenter, open-label, phase IIIb study","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin Ther"},{"issue":"7","key":"10.1016\/j.lpm.2016.09.012_bib0685","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.lpm.2016.09.012_bib0690","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/all.12914","article-title":"Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment","volume":"71","author":"Magnan","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.lpm.2016.09.012_bib0695","first-page":"CD010834","article-title":"Mepolizumab versus placebo for asthma","volume":"7","author":"Powell","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.lpm.2016.09.012_bib0700","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.anai.2011.03.005","article-title":"Persistence of effectiveness of bronchial thermoplasty in patients with severe asthma","volume":"107","author":"Castro","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.lpm.2016.09.012_bib0705","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3\u00a0trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.lpm.2016.09.012_bib0710","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1517\/14712598.2012.642359","article-title":"Benralizumab\u00a0\u2013\u00a0a humanized mAb to IL-5R\u03b1 with enhanced antibody-dependent cell-mediated cytotoxicity\u00a0\u2013\u00a0a novel approach for the treatment of asthma","volume":"12","author":"Ghazi","year":"2012","journal-title":"Expert Opin Biol Ther."},{"issue":"11","key":"10.1016\/j.lpm.2016.09.012_bib0715","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","article-title":"Benralizumab, an anti-interleukin-5\u00a0receptor \u03b1 monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study","volume":"2","author":"Castro","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.lpm.2016.09.012_bib0720","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ajem.2014.09.036","article-title":"A randomized trial of benralizumab, an anti-interleukin-5\u00a0receptor \u03b1 monoclonal antibody, after acute asthma","volume":"33","author":"Nowak","year":"2015","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.lpm.2016.09.012_bib0725","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5\u00a0receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3\u00a0trial","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2016.09.012_bib0730","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3\u00a0trial","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.lpm.2016.09.012_bib0735","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N Engl J Med"},{"issue":"10039","key":"10.1016\/j.lpm.2016.09.012_bib0740","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22\u00a0agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2016.09.012_bib0745","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1106469","article-title":"Lebrikizumab treatment in adults with asthma","author":"Corren","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.lpm.2016.09.012_bib0750","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/MCP.0000000000000005","article-title":"Periostin, a novel biomarker of TH2-driven asthma","volume":"20","author":"Parulekar","year":"2014","journal-title":"Curr Opin Pulm Med"},{"issue":"8","key":"10.1016\/j.lpm.2016.09.012_bib0755","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/thoraxjnl-2014-206719","article-title":"Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies","volume":"70","author":"Hanania","year":"2015","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.lpm.2016.09.012_bib0760","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1183\/09031936.00223411","article-title":"A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma","volume":"41","author":"Piper","year":"2013","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.lpm.2016.09.012_bib0765","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S2213-2600(15)00197-6","article-title":"Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Brightling","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.lpm.2016.09.012_bib0770","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaci.2011.03.043","article-title":"Allergen-induced expression of IL-25\u00a0and IL-25\u00a0receptor in atopic asthmatic airways and late-phase cutaneous responses","volume":"128","author":"Corrigan","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.lpm.2016.09.012_bib0775","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.4049\/jimmunol.0802387","article-title":"Increased expression of IL-33\u00a0in severe asthma: evidence of expression by airway smooth muscle cells","volume":"183","author":"Pr\u00e9fontaine","year":"2009","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.lpm.2016.09.012_bib0780","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/eji.201142018","article-title":"Pulmonary innate lymphoid cells are major producers of IL-5\u00a0and IL-13\u00a0in murine models of allergic asthma","volume":"42","author":"Klein Wolterink","year":"2012","journal-title":"Eur J Immunol"},{"issue":"6","key":"10.1016\/j.lpm.2016.09.012_bib0785","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.jaci.2007.07.051","article-title":"Blocking IL-25\u00a0prevents airway hyper-responsiveness in allergic asthma","volume":"120","author":"Ballantyne","year":"2007","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.lpm.2016.09.012_bib0790","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(16)30179-5","article-title":"Fevipiprant, a prostaglandin D2\u00a0receptor 2\u00a0antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial","volume":"4","author":"Gonem","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.lpm.2016.09.012_bib0795","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1164\/rccm.201308-1444LE","article-title":"Marked epithelial cell pathology and leukocyte paucity in persistently symptomatic severe asthma","volume":"188","author":"Bergqvist","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"21","key":"10.1016\/j.lpm.2016.09.012_bib0800","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1411776","article-title":"Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme","volume":"372","author":"Krug","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.lpm.2016.09.012_bib0805","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.jaci.2015.02.018","article-title":"Safety and tolerability of a novel inhaled GATA3\u00a0mRNA targeting DNAzyme in patients with TH2-driven asthma","volume":"136","author":"Homburg","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.lpm.2016.09.012_bib0810","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1164\/rccm.201109-1640OC","article-title":"A large subgroup of mild-to-moderate asthma is persistently non-eosinophilic","volume":"185","author":"McGrath","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2016.09.012_bib0815","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1164\/rccm.200906-0896OC","article-title":"Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program","volume":"181","author":"Moore","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.lpm.2016.09.012_bib0820","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/thx.2005.045260","article-title":"Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma","volume":"60","author":"Howarth","year":"2005","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.lpm.2016.09.012_bib0825","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/thx.2007.086314","article-title":"The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double-blind, randomised, placebo-controlled trial","volume":"63","author":"Morjaria","year":"2008","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.lpm.2016.09.012_bib0830","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1164\/rccm.200601-072OC","article-title":"The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma","volume":"174","author":"Erin","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.lpm.2016.09.012_bib0835","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1164\/rccm.200809-1512OC","article-title":"A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma","volume":"179","author":"Wenzel","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.lpm.2016.09.012_bib0840","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1365-2222.2012.04014.x","article-title":"Safety and efficacy of a CXCR2\u00a0antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial","volume":"42","author":"Nair","year":"2012","journal-title":"Clin Exp Allergy"},{"issue":"11","key":"10.1016\/j.lpm.2016.09.012_bib0845","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1164\/rccm.201212-2318OC","article-title":"Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17\u00a0receptor monoclonal antibody, in moderate-to-severe asthma","volume":"188","author":"Busse","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.lpm.2016.09.012_bib0850","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/thoraxjnl-2012-202698","article-title":"Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial","volume":"68","author":"Brusselle","year":"2013","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.lpm.2016.09.012_bib0855","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.rmr.2014.09.009","article-title":"[Bronchial thermoplasty in the treatment of severe adult asthma]","volume":"32","author":"Chanez","year":"2015","journal-title":"Rev Mal Respir"},{"issue":"12","key":"10.1016\/j.lpm.2016.09.012_bib0860","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1164\/rccm.200704-571OC","article-title":"Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma","volume":"176","author":"Pavord","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"13","key":"10.1016\/j.lpm.2016.09.012_bib0865","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa064707","article-title":"Asthma control during the year after bronchial thermoplasty","volume":"356","author":"Cox","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.lpm.2016.09.012_bib0435","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1378\/chest.14-2296","article-title":"Bronchial thermoplasty: ready for prime time\u00a0\u2013\u00a0the evidence is there!","volume":"147","author":"Castro","year":"2015","journal-title":"Chest"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498216302743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498216302743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T17:58:42Z","timestamp":1536256722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498216302743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":87,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0755498216302743"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2016.09.012","relation":{},"ISSN":["0755-4982"],"issn-type":[{"type":"print","value":"0755-4982"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les traitements du futur de l\u2019asthme s\u00e9v\u00e8re","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2016.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}